|
Published by: Global Markets Direct
Published: Oct. 31, 2012 - 51 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- House Dust Mite Allergy Overview
- Therapeutics Development
- An Overview of Pipeline Products for House Dust Mite Allergy
- House Dust Mite Allergy Therapeutics under Development by Companies
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- House Dust Mite Allergy Therapeutics – Products under Development by Companies
- Companies Involved in House Dust Mite Allergy Therapeutics Development
- Merck & Co., Inc.
- ALK-Abello A/S
- Stallergenes S.A.
- Circassia Holdings Ltd.
- ImVisioN Therapeutics AG
- Genetic Immunity, LLC
- ANERGIS SA
- Bial - Portela & Ca, S.A.
- Biomay AG
- House Dust Mite Allergy – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- ToleroMune House Dust Mite T Cell Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Mitizax - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Actair - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MK-8237 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- IVN-Mite - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- DermAll-HDM - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- House Dust Mite Peptide Carrier Fusion Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- House Dust Mite RNA Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- House Dust Mite Hypoallergenic Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AllerDM - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PL-103 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BIA-15-2957 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- House Dust Mite Allergy Therapeutics – Drug Profile Updates
- House Dust Mite Allergy – Product Development Milestones
- Featured News & Press Releases
- Oct 15, 2011: Circassia Initiates Key Phase II Clinical Trial Of House Dust Mite Allergy Treatment
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for House Dust Mite Allergy, H2 2012
- Products under Development for House Dust Mite Allergy – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Merck & Co., Inc., H2 2012
- ALK-Abello A/S, H2 2012
- Stallergenes S.A., H2 2012
- Circassia Holdings Ltd., H2 2012
- ImVisioN Therapeutics AG, H2 2012
- Genetic Immunity, LLC, H2 2012
- ANERGIS SA, H2 2012
- Bial - Portela & Ca, S.A., H2 2012
- Biomay AG, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- House Dust Mite Allergy Therapeutics – Drug Profile Updates
- List of Figures
- Number of Products under Development for House Dust Mite Allergy, H2 2012
- Products under Development for House Dust Mite Allergy – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractHouse Dust Mite Allergy – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'House Dust Mite Allergy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for House Dust Mite Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy. House Dust Mite Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for House Dust Mite Allergy.
- A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the House Dust Mite Allergy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
